Loading clinical trials...
Loading clinical trials...
The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patients with lymphoma.
The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patients with lymphoma are randomized into entecavir prophylaxis group or observation group. In entecavir prophylaxis group, entecavir 0.5 mg/day orally is initiate on day 1 of the first course of antitumor therapy, and will be continued until at least 6 months after completion of antitumor therapy. In observation group, entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China
307 Hospital of the Chinese People's Liberation Army
Beijing, Beijing Municipality, China
309 Hospital of the Chinese People's Liberation Army
Beijing, Beijing Municipality, China
Aerospace Central Hospital
Beijing, Beijing Municipality, China
Air Force General Hospital of the Chinese People's Liberation Army
Beijing, Beijing Municipality, China
Beijing Hospital
Beijing, Beijing Municipality, China
Cancer Institute & Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
First Hospital affiliated to General Hospital of the Chinese People's Liberation Army
Beijing, Beijing Municipality, China
General Hospital of Chinese People's Liberation Army
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Start Date
January 1, 2013
Primary Completion Date
December 1, 2017
Completion Date
December 1, 2017
Last Updated
January 10, 2017
190
ESTIMATED participants
Entecavir prophylaxis
DRUG
Observation arm
DRUG
Lead Sponsor
Peking University
NCT07024641
NCT06671093
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07275554